New potential treatment target for patients with inflammatory bowel disease
A new study published today in Nature Medicine could change the lives of millions of people living with inflammatory bowel diseases (IBD) who don’t respond to the current standard of care.
Read moreNIHR funding for musculoskeletal and inflammation research
The University of Oxford and Oxford University Hospitals NHS Foundation Trust (OUH) have won £113.7 million to support groundbreaking medical research.
Read moreM40 Alliance forms to accelerate arthritis therapy
A new partnership has been formed between the Universities of Oxford and Birmingham to speed up the development of novel treatments for arthritis, supported by a £7 million investment from the Kennedy Trust for Rheumatology Research.
Read moreKennedy Institute of Rheumatology
We are a world-leading basic and translational inflammatory sciences centre. The three major themes of our research - immunity and microbiome, inflammation biology and tissue remodelling and repair - are relevant for a diverse range of chronic inflammatory disorders, including arthritis, inflammatory bowel disease, tissue fibrosis and certain types of cancer. We apply state-of-the-art technologies in analysis of disease models and patient tissue samples to understand why disease develops and to reveal new diagnostic markers and targets for therapy. Strategic partnerships with nearby clinical centres such as the Nuffield Orthopaedic Centre and the John Radcliffe Hospital facilitate scientific translation from bench to bedside.
Recent Publications
-
Oncostatin M drives intestinal inflammation and predicts response to tumor necrosis factor-neutralizing therapy in patients with inflammatory bowel disease.
West NR. et al, (2017), Nat Med, 23, 579 - 589
-
Sterile signals generate weaker and delayed macrophage NLRP3 inflammasome responses relative to microbial signals.
Bezbradica JS. et al, (2017), Cell Mol Immunol, 14, 118 - 126
-
A critical role for IRF5 in regulating allergic airway inflammation.
Byrne AJ. et al, (2017), Mucosal Immunol, 10, 716 - 726
-
T-bet is a key modulator of IL-23-driven pathogenic CD4(+) T cell responses in the intestine.
Krausgruber T. et al, (2016), Nat Commun, 7
-
Distinct microenvironmental cues stimulate divergent TLR4-mediated signaling pathways in macrophages.
Piccinini AM. et al, (2016), Sci Signal, 9
OA centre
Our Arthritis Research UK Centre of Excellence aims to develop new treatments for arthritis, improving healthcare and transforming people's lives.
Latest news
Professor Powrie to become new Wellcome Governor
19 July 2017
research highlights
Effects of dopamine in immunological synapse formation.
The neurotransmitter dopamine has been shown to play a key role in the formation of immune responses in a major study published this week in Nature. Research in the Dustin lab has demonstrated for the first time how human immune cells use neurotransmitters, including dopamine, in specialised patches on the cell surface to amplify the immune response. This work can now be used as a basis for the development of new therapies to treat immune diseases. Read full paper.
DYNAMICS OF MACROPHAGE ACTIVATING AND INHIBITORY RECEPTOR NANOCLUSTERS
Macrophages contribute to host defence through the uptake – or so called phagocytosis – of pathogens and other harmful foreign particles. In the JCB, the Davis and Dustin labs use super resolution microscopy to show how activating and inhibitory receptors are reorganised at a nanometer scale to integrate positive and negative signals for proper regulation of the macrophage phagocytic response. Read full paper.